Advancing oncology clinical development

Unlock the Potential of Your Oncology Clinical Trials with IQVIA Laboratories

At IQVIA Laboratories, we are your dedicated partner in oncology clinical development. We recognize the pivotal role that biomarkers and emerging technologies play throughout the clinical development continuum. Our commitment is to deliver high-quality laboratory data that supports exploratory and secondary objectives, as well as patient selection and stratification.

Our global laboratory network is equipped with a comprehensive array of validated assays, utilizing the latest technologies in IHC, FISH, molecular diagnostics, NGS, circulating protein markers, and flow cytometry.

With an extensive network of anatomical pathologists and accredited, certified testing laboratories, IQVIA Laboratories delivers biomarker data in  industry-leading turnaround times. This efficiency aids in the timely recruitment of patients at clinical sites, facilitating the provision of targeted investigational therapeutics.

From Phase I to Phase III studies, IQVIA Laboratories is equipped to support your needs with a robust team of subject matter experts, skilled laboratory personnel, and extensive regulatory experience. Our global lab network ensures reliable laboratory data, making us your trusted partner in clinical development.

Precision Medicine

Our assay validation and testing services encompass flow cytometry, immunoassay, IHC, FISH, NGS, and molecular technologies, supporting clinical trials globally with laboratories in the US, EU, Asia, and China.

Often, these assays are utilized for precision medicine and potentially companion diagnostics. We have supported nearly 200 CDx oncology projects across five CDx lab locations. Our labs have been qualified by the principal IVD companies.

At our labs performing CDx work, there is a dedicated CDx Operational Team, including project management and principal investigators. Our laboratories have provided the CDx testing that has supported seven CDx approvals.

Cell and Gene Therapy

Our cell and gene therapy capabilities have supported over 50 therapeutic programs, including treatments for hematological malignancies and rare diseases. With laboratories across the  US, EU, and China, we provide essential testing data for anti-drug antibodies, cytokines, pharmacokinetics, and immune profiling.

For CAR-T and CAR-NK therapies, our extensive flow cytometry capabilities deliver critical data on CAR-T enumeration and persistence, target phenotyping, and MRD assessment.

IQVIA Laboratories, leveraging its global network and industry-leading subject matter experts, is ideally positioned to shape, validate, and deliver biomarker assessments. We offer flexible, integrated cell and gene therapy development solutions throughout the drug development journey, from the pre-clinical phase through post-approval.

Our Work

The Clinical Trial Testing Services provided by IQVIA Laboratories deliver essential laboratory data that supports clinical development, ultimately bringing new and better medicines to the patients we serve.

While oncology is our dominant therapeutic area, often incorporating precision medicine goals, our work spans all therapeutic areas. We support various drug modalities, from large and small molecules to cell and gene therapies, as well as recent advancements in bispecifics and antibody-drug conjugates.

Our industry-leading subject matter experts and dedicated delivery teams are committed to providing high-quality laboratory data in a timely manner, supporting the advancement of therapeutics from clinical development to approval.